Welcome to our dedicated page for PMGC Holdings news (Ticker: elab), a resource for investors and traders seeking the latest updates and insights on PMGC Holdings stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PMGC Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PMGC Holdings's position in the market.
NorthStrive Biosciences, a subsidiary of PMGC Holdings (NASDAQ: ELAB), has completed Phase I strategic review of EL-22, their oral myostatin-engineered probiotic. The study, conducted with Yuva Biosciences using their MitoNova™ AI technology, focused on EL-22's potential to combat muscle loss associated with GLP-1 weight loss drugs and age-related sarcopenia.
EL-22 uses genetically engineered Lactobacillus casei to stimulate the gut immune system against myostatin, a muscle growth inhibitor. The preclinical studies in mdx mice showed promising effects on antibody production, serum CK, body weight, motor function, and muscle histology. The company plans to initiate a Phase 2 proof-of-concept trial targeting GLP-1 users and pursue IND filing in the United States.
PMGC Holdings Inc. (NASDAQ: ELAB) has filed its Q1 2025 Quarterly Report on Form 10-Q with the SEC. The company operates through multiple subsidiaries including NorthStrive Biosciences, focused on aesthetic medicines and developing EL-22 for muscle preservation in obesity treatments; PMGC Research, leveraging Canadian research grants; and PMGC Capital, a multi-strategy investment firm. Management reports the company is well-capitalized with a strong balance sheet. Notably, PMGC announced a non-binding LOI on April 16, 2025, to acquire a profitable U.S.-based IT custom packaging company, aligning with its strategy of pursuing B2B acquisitions to drive revenue growth and enhance shareholder value.
PMGC Capital LLC, a subsidiary of PMGC Holdings Inc. (ELAB), announced plans to file a Schedule 13D disclosing a 5.09% ownership stake in Alaunos Therapeutics (TCRT). The stake represents 83,500 shares of the clinical-stage oncology-focused cell therapy company, based on Alaunos' 1,639,521 outstanding shares as of May 5, 2025.
PMGC Capital believes Alaunos is undervalued and sees significant potential for shareholder value creation. Alaunos is currently exploring strategic alternatives, including mergers, acquisitions, asset sales, and strategic partnerships. PMGC Capital plans to engage with Alaunos' management to explore strategic opportunities, particularly in fintech and cryptocurrency sectors.
Northstrive Biosciences, a subsidiary of PMGC Holdings (NASDAQ: ELAB), has signed a binding term sheet with Modulant Biosciences for exclusive global licensing rights of EL-22 in animal health applications. The agreement covers worldwide rights (excluding South Korea) for developing and commercializing EL-22 as a feed additive, focusing on a probiotic approach to muscle preservation in livestock.
The intellectual property includes U.S. Patent 8,470,551 and two patent applications. Under the financial terms, Modulant will pay Northstrive a share of revenues from sublicensing and commercial activities, with the royalty rate decreasing after reaching a certain threshold. The agreement also includes provisions for co-ownership of new intellectual property and annual updates on commercialization efforts.
Northstrive Biosciences, a subsidiary of PMGC Holdings (NASDAQ: ELAB), has filed four new patent applications for its drug candidates EL-22 and EL-32. The patents cover two key areas: animal market applications and muscle loss treatment in obese patients, particularly in combination with GLP-1 receptor agonists.
The patent applications include:
- EL-22 for muscle growth in animals
- EL-32 as a standalone therapy for obesity-related muscle loss
- EL-32 in combination with GLP-1 drugs
- EL-32 as an animal feed additive
These additions bring Northstrive's intellectual property portfolio to 8 patent applications and 5 issued patents, with protection across major markets including the USA, Japan, China, and Korea. The company's engineered probiotic platform aims to preserve muscle mass while reducing fat mass in obesity treatment, with potential expansion into animal health markets.
Northstrive Biosciences, a subsidiary of PMGC Holdings (NASDAQ: ELAB), announced that Co-Founder Deniel Mero was featured in a Bear Bull Traders interview discussing recent FDA preliminary meeting responses. The responses support their plans for EL-22, a myostatin-engineered probiotic treatment designed to preserve muscle during weight loss with GLP-1 receptor agonists.
The FDA's feedback supports moving forward with an Investigational New Drug (IND) application for a Phase 2 clinical trial targeting overweight or obese patients. Bear Bull Traders, founded by Andrew Aziz, reaches 595,000 YouTube subscribers and maintains a network of over 7,000 active members and 100,000 newsletter subscribers globally.
Northstrive Biosciences, a subsidiary of PMGC Holdings (NASDAQ: ELAB), received positive FDA preliminary responses regarding their pre-IND meeting for EL-22, a novel engineered probiotic designed for obesity treatment in combination with GLP-1 receptor agonists.
The FDA's feedback supported that:
- Pharmacology studies demonstrate EL-22 activity
- Nonclinical studies adequately support safety and activity in overweight/obese populations
- Phase 1 study data and nonclinical studies appear sufficient for initiating Phase 2 trials
EL-22 targets the myostatin pathway to support muscle health during weight loss treatments. The company plans to file an IND application in 2025 to initiate Phase 2 clinical trials. Previous Phase 1 trials in South Korea showed the treatment was generally well-tolerated and safe in healthy volunteers.
PMGC Holdings Inc. (NASDAQ: PMGC) has announced signing a non-binding Letter of Intent (LOI) to acquire a U.S.-based custom IT packaging company. The acquisition target brings significant operational experience with nearly 15 years of history and serves over 300 commercial clients including data centers, technology manufacturers, and IT service providers.
The target company demonstrates strong market presence with 90% U.S.-based revenue and maintains recurring business relationships. The company is notably cash-flow positive, indicating established operational stability.
Northstrive Biosciences, a subsidiary of PMGC Holdings (NASDAQ: ELAB), has entered into a Development and License Agreement with Yuva Biosciences to develop AI-powered therapies for obesity and cardiometabolic diseases. The collaboration will utilize YuvaBio's proprietary MitoNova™ platform to discover novel pharmaceutical treatments.
The partnership focuses on developing compounds that promote mitochondrial health and target cellular aging. YuvaBio will provide Northstrive with exclusive worldwide licensing rights for therapeutic products in cardiac diseases and obesity. The multi-phase collaboration includes in silico modeling, virtual compound screening, and experimental testing.
The agreement includes: (1) an upfront fee and phase-completion payments, (2) developmental milestone payments, and (3) royalties on net sales of therapeutic products containing compounds identified through the program.
FAQ
What is the current stock price of PMGC Holdings (elab)?
What is the market cap of PMGC Holdings (elab)?
